About 18 results found for searched term "ERK2-IN-3" (0.136 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49701 | ERK1/2 inhibitor 3 | ERK |
| ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. | ||
| M49707 | ERK2-IN-3 | ERK |
| ERK2-IN-3 is a inhibitor of ERK2, and inhibits Erk2WT and Erk2DS1 activation loop phosphorylation, with IC50 of 5 μM and 42 nM, respectively. | ||
| M4428 | Senkyunolide-I | Caspase |
| Senkyunolide I can be isolated from Ligusticum chuanxiong Hort and is an antimigraine compound. Senkyunolide I protects rat brain from focal cerebral ischemia-perfusion injury by up-regulating P-ERK1/2, Nrf2/HO-1 and inhibiting Caspase 3. | ||
| M4705 | Asperosaponin-VI | Caspase |
| Akebia saponin D | ||
| Asperosaponin-VI induces osteoblast differentiation through BMP‐2/p38 and ERK1/2 pathway. Asperosaponin Ⅵ inhibits apoptosis in hypoxia-induced cardiomyocyte by increasing the Bcl-2/Bax ratio and decreasing active caspase-3 expression, as well as enhancing of p-Akt and p-CREB. | ||
| M4819 | XMD17-109 | ERK |
| ERK5-IN-1 | ||
| XMD17-109 (ERK5-IN-1) is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 μM in HEK293 cells. | ||
| M5345 | Ulixertinib (BVD-523) | ERK |
| VRT752271; BVD523, Ulixertinib | ||
| VRT752271 (BVD-523, Ulixertinib) is an orally available, highly selective, ATP-competitive, reversible ERK1/2 inhibitor with an IC50 of <0.3 nM for ERK2 inhibition. | ||
| M9688 | ERK5-IN-2 | ERK |
| ERK5-IN-2 is a selective, orally active, sub-micromolar ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. | ||
| M9803 | MK-8353 | ERK |
| SCH900353 | ||
| MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK1/2 inhibitor, with IC50 values of 23.0 nM and 8.8 nM, respectively. | ||
| M11021 | (rel)-AR234960 | ERK |
| (rel)-AR234960 is the relatively active configuration of AR234960. AR234960 is a non-peptide MAS (a G protein coupling receptor) agonist that upregulates CTGF mRNA and protein levels through the ERK1/2 signaling pathway in HEK293-MAS cells and adult myocardial fibroblasts. | ||
| M14152 | ERK1/2 inhibitor 1 | ERK |
| ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively. | ||
| M14155 | Ulixertinib hydrochloride | ERK |
| BVD-523 hydrochloride; VRT752271 hydrochloride | ||
| Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. | ||
| M20614 | NSC-87877 disodium salt | Phosphatase |
| NSC-87877 disodium is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively. NSC-87877 disodium salt also inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation. | ||
| M21591 | RLX-33 | RXFP |
| RLX-33 is a potent and selective blood-brain barrier permeable relaxin family peptide 3 (RXFP3) antagonist that also blocks relaxin 3 (Relaxin 3) -induced ERK1/2 phosphorylation. The IC50 phosphorylated RXFP3, ERK1 and ERK2 were 2.36μM, 7.82μM and 13.86μM, respectively. RLX-33 can block the increase of food intake in rats induced by RXFP3 selective agonist R3/I5. RLX-33 can be used in the study of metabolic syndrome. | ||
| M28221 | OSU-2S | PKC |
| OSU-2S is a potent PKCδ activator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib. OSU-2S induces Apoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity. | ||
| M30350 | E6201 | MEK |
| ER-806201 | ||
| E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC50 value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC50 value of 19 nM. Anti-tumor and anti-psoriasis efficacy. | ||
| M49695 | ACA-28 | ERK |
| ACA-28 is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth by inducing apoptosis with ERK hyperactivation ACA-28 inhibits cell growth of melanoma cells (SK-MEL-28) and normal melanocytes (NHEM), with IC50 values of 5.3 and 10.1 μM, respectively. | ||
| M49720 | STE-MEK1(13) | ERK |
| STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH?) is a cell permeable ERK1/2 inhibitor (IC50: 13-30?μM). | ||
| M54609 | Capmatinib dihydrochloride hydrate | c-Met |
| INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate | ||
| Capmatinib dihydrochloride hydrate is a potent, orally active, selective, ATP-competitive c-Met kinase inhibitor (IC50=0.13 nM) that inhibits the phosphorylation of c-MET, as well as downstream effector proteins of the c-MET pathway, such as ERK1/2, AKT, FAK, In addition, Capmatinib dihydrochloride hydrate effectively inhibited the proliferation and migration of c-Met-dependent tumor cells, induced apoptosis, and demonstrated antitumor activity in a mouse model of tumor. Capmatinib dihydrochloride hydrate is mainly metabolized by CYP3A4 and aldehyde oxidase. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
